Profile data is unavailable for this security.
About the company
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.
- Revenue in USD (TTM)4.35bn
- Net income in USD1.05bn
- Incorporated1999
- Employees13.90k
- LocationEdwards Lifesciences Corp1 Edwards WayIRVINE 92614-5688United StatesUSA
- Phone+1 (949) 250-2500
- Fax+1 (302) 655-5049
- Websitehttps://www.edwards.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zimmer Biomet Holdings Inc | 7.98bn | 1.13bn | 18.52bn | 19.90k | 16.39 | 1.49 | 8.67 | 2.32 | 5.47 | 5.47 | 38.61 | 60.14 | 0.3274 | 0.9871 | 6.05 | 401,115.60 | 4.64 | 1.45 | 5.28 | 1.60 | 71.30 | 70.72 | 14.18 | 4.69 | 0.6796 | 7.54 | 0.3986 | 53.74 | 0.6215 | 11.30 | 405.10 | 9.46 | 16.05 | 1.76 |
| ResMed Inc. | 2.78bn | 460.37m | 20.58bn | 7.24k | 44.83 | 9.11 | 33.09 | 7.39 | 3.17 | 3.14 | 19.21 | 15.62 | 0.678 | 3.39 | 5.50 | 384,586.30 | 11.21 | 12.58 | 12.65 | 14.69 | 58.97 | 58.67 | 16.53 | 18.16 | 1.85 | 10.13 | 0.3653 | 48.26 | 11.38 | 10.88 | -9.34 | 3.56 | -0.9581 | 8.16 |
| DexCom, Inc. | 1.48bn | 101.10m | 23.34bn | 3.90k | 235.27 | 26.45 | 155.80 | 15.81 | 1.08 | 1.08 | 16.11 | 9.64 | 0.6848 | 5.57 | 5.75 | 378,461.50 | 4.69 | -1.96 | 5.42 | -2.31 | 64.07 | 65.65 | 6.85 | -2.24 | 5.13 | 4.10 | 0.5491 | -- | 43.08 | 41.61 | 179.29 | -- | 61.86 | -- |
| Edwards Lifesciences Corp | 4.35bn | 1.05bn | 35.79bn | 13.90k | 34.90 | 8.70 | 31.42 | 8.23 | 4.95 | 4.93 | 20.49 | 19.84 | 0.7362 | 1.79 | 8.69 | 312,805.80 | 17.77 | 15.19 | 20.93 | 18.11 | 74.37 | 74.39 | 24.14 | 21.99 | 2.60 | -- | 0.1253 | 0.00 | 16.79 | 13.36 | 42.24 | 5.29 | 24.33 | -- |
| Baxter International Inc | 11.36bn | 807.00m | 39.90bn | 50.00k | 51.08 | 5.05 | 24.97 | 3.51 | 1.54 | 1.92 | 21.99 | 15.57 | 0.6701 | 3.95 | 6.08 | 227,240.00 | 4.82 | 9.52 | 5.87 | 11.99 | 42.22 | 42.29 | 7.19 | 16.39 | 1.81 | 16.60 | 0.4034 | 24.49 | 2.37 | 1.17 | -40.00 | 12.04 | -18.18 | -16.14 |
| Boston Scientific Corporation | 10.74bn | 4.70bn | 42.24bn | 36.00k | 9.07 | 3.03 | 7.40 | 3.93 | 3.33 | 3.33 | 7.61 | 9.95 | 0.4164 | 2.32 | 6.25 | 298,194.40 | 18.23 | 7.37 | 22.68 | 9.31 | 70.37 | 70.79 | 43.78 | 16.23 | 0.6412 | 3.00 | 0.419 | 0.00 | 9.28 | 7.78 | 193.02 | -- | 16.44 | -- |
| Intuitive Surgical, Inc. | 4.48bn | 1.38bn | 53.50bn | 7.33k | 39.70 | 6.43 | 33.48 | 11.95 | 11.54 | 11.54 | 37.48 | 71.24 | 0.5095 | 2.72 | 6.75 | 611,315.90 | 15.72 | 15.14 | 17.60 | 16.92 | 69.45 | 69.30 | 30.85 | 29.35 | 3.95 | -- | 0.00 | 0.00 | 20.25 | 16.01 | 22.24 | 26.92 | 32.15 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2019 | 15.90m | 7.62% |
| BlackRock Fund Advisorsas of 31 Dec 2019 | 11.32m | 5.43% |
| SSgA Funds Management, Inc.as of 31 Dec 2019 | 8.92m | 4.28% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2019 | 7.89m | 3.78% |
| Sands Capital Management LLCas of 31 Dec 2019 | 6.07m | 2.91% |
| Jennison Associates LLCas of 31 Dec 2019 | 4.89m | 2.35% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2019 | 4.67m | 2.24% |
| Wellington Management Co. LLPas of 31 Dec 2019 | 4.46m | 2.14% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2019 | 4.46m | 2.14% |
| Walter Scott & Partners Ltd.as of 31 Dec 2019 | 4.35m | 2.09% |
